Amgen

Pullback in pharma has created a compelling buying opportunity

by

The fundamentals are good for the health care sector in general.  Recent news articles on drug pricing/gouging are not likely to effect meaningful change for the overall group dynamics in my opinion or that any changes may be long time in coming and tempered far below market expectations. It’s true that it may compress multiple prices for a while as Evercore #1 ranked biotech analyst Mark Schoenebaum said on CNBC today but I agree with him, its really about innovation.  His favorite picks are Gilead GILD and maintains a price target of $115 on the stock.  I am not as enthusiastic … Read more

‘s drop in the S&P 500 worst day since August 2011

by

Thursday’s 43.88 pt. plunge in the S&P 500 was  the worst one day drop in actual points (not percentages) since August 2011.   That was when the U.S. got their debt downgraded.  Volume was not out of the ordinary either so there is no sign of a capitulation sell off.  Reasons for the plunge vary widely but most explanations tied back to sinking price of crude oil, China slow down or worse, and fear of the Fed raising rates, etc.  As they say the usual suspects. The Dow lost nearly a hundred points in the last 15 minutes.  It felt like margin call selling … Read more